In a surprising turn of events, Novo Nordisk has dropped its patent infringement lawsuit against Hims & Hers after the two companies reached an agreement. The deal will now allow Novo Nordisk’s branded weight loss medicines to be sold through the Hims platform, putting an end to the dispute over off-brand versions of the medication.

The FDA’s announcement that GLP-1 drugs were no longer in shortage in 2024 has led to changes in the market, prompting companies like Hims to adjust their strategies. As part of the agreement, Hims will offer both oral and injectable versions of Wegovy and Ozempic on its platform, while also ceasing the advertising of compounded GLP-1 drugs. Despite this development, Novo Nordisk has reserved the right to refile its lawsuit in the future, signaling that the situation may not be fully resolved.